Vioxx

Evidence of cardiovascular risks associated with taking Vioxx, the popular, nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer, Merck & Co. Inc., voluntarily pulled the drug from the market, according to new data.  

Evidence of cardiovascular risks associated with taking Vioxx, the popular, nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer, Merck & Co. Inc., voluntarily pulled the drug from the market.  

Vioxx side effects could have been known years earlier Vioxx was a blockbuster drug. Launched by Merck & Co., Inc., in 1999 as a treatment for painful arthritis, its annual sales soon reached $2 billion. The benefits were much the same as other anti-inflammatory painkillers, which sold for a fraction of the cost, but Vioxx (the generic name is rofecoxib) was designed to be less irritating...  

The Food and Drug Administration still hasn't restructured its staff to better monitor drug safety, more than three years after experts recommended key changes in the wake of the Vioxx scandal. That's according to congressional investigators who found that... Food and Drug Administration - Rofecoxib - Pharmacovigilance - Health - United States  

We have long been writing about the links between Merck’s blockbuster nonsteroidal, anti-inflammatory medication Vioxx (rofecoxib) and negative cardiac events. Now, according to Science Daily, a study has found that evidence of cardiovascular risks linked to Vioxx might have been realized almost four years before Merck & Co. Inc., pulled the drug from the market. Vioxx [...]  

Boston (DbTechNo) - It appears that heart risks associated with Vioxx were known about up to 3 years before Merck pulled their drug from the market. The painkiller was pulled from the market back in 2004, after it became apparent that the drug had severe heart attack risk in patients who received it. This news comes from [...]  

Evidence of cardiovascular risks associated with taking Vioxx, the popular, nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer, Merck & Co. Inc., voluntarily pulled the drug from the market, according to a new study led by Dr. Joseph Ross of Mount Sinai School of Medicine.  

WASHINGTON (AP) — Lawyers for Merck & Co. have told the Supreme Court that investors waited too long to sue over its warnings about the risks of its former blockbuster painkiller Vioxx before it was pulled from the market. Merck wants the high court to throw out an investors' class-action securities lawsuit. They sued because of the tens of billions of dollars in shareholder value lost overnight after Merck pulled Vioxx off the...  

CHICAGO – Clinical trial data indicated an association between the anti-inflammatory medication rofecoxib and cardiovascular risk as early as December 2000, before the product was taken off the market in September 2004, according to a report in the November 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Rofecoxib was introduced to the market in May 1999 and quickly became a commercial success, with sales...  

WASHINGTON — Lawyers for Merck & Co. have told the Supreme Court that investors waited too long to sue over its warnings about the risks of its former blockbuster painkiller Vioxx before it was pulled from the market.  

Evidence that the painkiller Vioxx might increase the risk of heart attacks and strokes emerged nearly four years before the drug was voluntarily withdrawn from the market, research has shown. Vioxx, the brand name for rofecoxib, was designed to fight the pain of arthritis. It was launched in May 1999 by Merck & Co Inc. But in September 2004, Merck voluntarily pulled Vioxx following a large trial that was halted early after finding evidence...  

Before the headlines hit about the dangers of using Vioxx (rofecoxib), researchers were already aware, say news reports. Vioxx, a non-steroidal anti-inflammatory (NSAID), was made by Merck & Co. Inc., and introduced to the American market in 1999. The company then voluntarily pulled the drug from the market in September 2004, after there were multiple reports of increased risk of heart attack and stroke associated with long-term, high-dose use...  

"Court hears Vioxx lawsuit arguments": Jesse J. Holland of The Associated Press has a report that begins, "Lawyers for Merck & Co. told the Supreme Court Monday investors waited too late and didn't do all of the necessary investigations to...  

WHITEHOUSE STATION, N.J., Merck today presented oral arguments in the U.S. Supreme Court in Merck & Co., Inc., v. Richard Reynolds. - - The Supreme Court is reviewing a decision reinstating a securitie...  

Readers of this blog are, by now, aware of the many issues surrounding Merck’s blockbuster nonsteroidal, anti-inflammatory medication Vioxx (rofecoxib) and negative cardiac events. The cardiac problems associated with Vioxx, and its subsequent withdrawal from the market, spawned scores of lawsuits. These include Merck shareholder lawsuits, which were recently the subject of oral [...]  

On Monday, Merck & Co., and the investors who filed securities suits against it, had their day in court. Investors in Merck are suing the company over the misrepresentation of the safety of Vioxx (or lack thereof) which allegedly caused...  

Lawyers for Merck & Co. have told the Supreme Court that investors waited too long to sue over its warnings about the risks of its former blockbuster painkiller Vioxx before it was pulled from the market.  

WASHINGTON - Lawyers for Merck & Co. told the U.S. Supreme Court today that investors waited too long and didn't do all of the necessary investigations to sue the drugmaker over whether it properly warned about the risks of its blockbuster painkiller Vioxx.  

The Food and Drug Administration still hasn't restructured its staff to better monitor drug safety, more than three years after experts recommended key changes in the wake of the Vioxx scandal.That's according to congressional investigators who found that the FDA has yet to follow through on changes suggested in 2006 to help the agency detect problems with drugs taken by millions of Americans. Those recommendations came after the embarrassing...  

U.S. Supreme Court justices seemed reluctant Monday to give the pharmaceutical company Merck & Co. a "statute of limitations" way out of defending against a securities fraud class action involving Vioxx. The Court heard arguments in the latest round in a continuing battle over how easy or hard it should be to file class actions. Companies want speed, while shareholder and consumer groups insist ...  

Background  In September 2004, rofecoxib was voluntarily withdrawn from the worldwide market. Our objective was to determine whether and when analysis of published and unpublished placebo-controlled trials could have revealed cardiovascular risk associated with rofecoxib before its withdrawal as an example to inform future postmarket pharmaceutical safety surveillance efforts. Methods  We conducted a cumulative subject-level pooled analysis of...  

[JURIST] The US Supreme Court [official website; JURIST news archive] heard oral arguments [day call, PDF; merit briefs] Monday in two cases. In Graham County Soil & Water Conservation Dist. v. United States ex rel. Wilson [oral arguments transcript, PDF; JURIST report], the Court heard arguments on the scope of the public disclosure jurisdictional bar [31 USC § 3730(e)(4)(A) text] of the False  

WASHINGTON (AP) — Lawyers for Merck & Co. told the Supreme Court Monday investors waited too late and didn't do all of the necessary investigations to sue the drug maker over whether it properly warned about the risks of its blockbuster painkiller Vioxx.  

Lawyers for Merck & Co. told the Supreme Court on Monday that investors waited too late and didn’t do all of the necessary investigations to sue the drugmaker over whether it properly warned about the risks of its blockbuster painkiller Vioxx.  

Washington - The Food and Drug Administration still hasn't restructured its staff to better monitor drug safety, more than three years after experts recommended key changes in the wake of the Vioxx scandal. That's according to congressional investigators who found that the FDA has yet to follow through on changes suggested in 2006 to help the agency detect problems with drugs taken by millions of Americans. Those recommendations came after...  

WHITEHOUSE STATION, N.J. (AP) — Merck & Co. said Monday a district court judge in Texas dismissed all claims in a state Medicaid lawsuit over the painkiller Vioxx.Merck said Travis County, Texas District Court Judge Scott H. Jenkins granted the company's motion for summa....  

The Vioxx scandal, and the Food & Drug Administration’s (FDA) role in it, has not brought about much change at the agency, according to a new government report. Vioxx was approved for use in 1999, and quickly became a bestseller for Merck, with annual sales of $2.5 billion; however, the painkiller was pulled off the market [...]  

The Vioxx scandal, and the Food & Drug Administration’s (FDA) role in it, has not brought about much change at the agency, according to a new government report. Vioxx was approved for use in 1999, and quickly became a bestseller for Merck, with annual sales of $2.5 billion; however, the painkiller was pulled off the market [...]  

Merck (MRK) got a rough ride at the U.S. Supreme Court on Monday. The justices ridiculing the company’s argument that investors in its stock should have sued the company earlier over its misrepresentations about Vioxx even though they would not have had the evidence for their suits to succeed at that time.  

AbbottAUSTIN (Legal Newsline)-A Texas judge has dismissed a lawsuit brought by the state attorney general against drugmaker Merck & Co. over its now-withdrawn painkiller Vioxx.In a 2005 lawsuit, Texas Attorney General Greg Abbott had sought a refund on behalf of the state for money spent on the drug. The lawsuit also sought damages and penalties for alleged violations of the Texas Medicaid Fraud Prevention Act.Travis County Judge Scott...  

Der US-Pharmakonzern Merck & Co. hat im Fall um das Schmerzmittel Vioxx eine juristische Niederlage in Deutschland erlitten. Das Oberlandesgericht Brandenburg verpflichtete die deutsche Merck-Tochter MSD Sharp & Dohme nach Informationen des Berliner "Tagesspiegel" (Freitagausgabe) dazu, alle internen Unterlagen über Nebenwirkungen des Schmerzmittels herauszugeben. Das Blatt beruft sich auf das Gericht. Nach Berichten über ein möglicherweise...  

Congressional investigators say the Food and Drug Administration has not followed through on changes suggested three years ago to better monitor drug safety. The recommendations came after an embarrassing and dangerous episode with Vioxx. The FD  

U.S. Supreme Court justices seemed reluctant Monday to give the pharmaceutical company Merck & Co. a "statute of limitations" way out of defending against a securities fraud class action involving Vioxx.  

"Some Justices Voice Skepticism of Merck in Vioxx Case": Brent Kendall of Dow Jones Newswires has this report. And law.com's Tony Mauro reports that "High Court Seems Unconvinced by Merck in Vioxx Arguments."...  

CHICAGO (Reuters) - Heart risks from taking Merck & Co Inc's painkiller Vioxx could have been detected more than three years before the company withdrew the drug from the market in September 2004, had the data been openly available, U.S. researchers said on Monday.  

The Money TimesMerck & Co wins Vioxx court case, dismisses meta-analysis claimPharma TimesOn the day it won a court case in Texas over Vioxx, Merck & Co has been hit by the publication of a meta-analysis which claims that a cardiovascular risk ...Vioxx risks could have been detected earlier: studyReutersBusiness news in briefPhiladelphia InquirerMerck denies knowing risk of VioxxUnited Press InternationalRTT News -Drug Store News (blog...  

By ASSOCIATED PRESS ASSOCIATED PRESS Lawyers for Merck & Co. told the Supreme Court on Monday that investors waited too long and didn't do all of the necessary investigations to sue the drug maker...  

NEW YORK (Reuters) - A Texas court has dismissed a lawsuit brought by the state against drugmaker Merck & Co that sought a refund for money spent on the withdrawn Vioxx pain treatment, the company said on Monday.  

Lawyers for Merck told the Supreme Court Monday investors waited too late and didn't do all of the necessary investigations to sue the drugmaker over whether it properly warned about the risks of its blockbuster painkiller Vioxx.  

A new report published in the Archives of Internal Medicine has found that drugmaker Merck knew about the increased cardiovascular risks of its arthritis drug Vioxx years before the company voluntarily recalled the medicine.  

WHITEHOUSE STATION, N.J. - Merck & Co. said today that a district court judge in Texas dismissed all claims in a state Medicaid lawsuit over the painkiller Vioxx.  

The Food and Drug Administration still hasn't restructured its staff to better monitor drug safety, more than three years after experts recommended key changes in the wake of the Vioxx scandal.  

The Food and Drug Administration still hasn't restructured its staff to better monitor drug safety, more than three years after experts recommended key changes in the wake of the Vioxx scandal.  

NEW YORK, Nov. 24 (UPI) -- Merck & Co. is disputing it knew Vioxx significantly increased the risk of heart attacks at least three years before it was pulled off the market.  

The risks of taking anti-inflammatory drug Vioxx could have been detected nearly four years before the drug was pulled from the market, according to analysis of nearly 30 clinical trials.The findings, published in the Archives of Internal Medicine on Monday, analyzed 30 Vioxx trials involving around 20,000 individuals and fund evidence of the drug's risks from as early as 2000.The Merck-made drug was pulled in 2004 after it was linked with...  

Merck said today that Travis County, Texas District Court Judge Scott H. Jenkins granted Merck's motion for summary judgment, dismissing all claims in a VIOXX-related lawsuit filed on behalf of the State of Texas.  

It's been 5 years since the then CEO of giant drug-maker Merck, Raymond Gilmartin, testified to the US Senate Finance Committee regarding evidence showing that Vioxx increases the risk of death due to heart attacks, strokes and other cardiovascular events. In a Summary of Prepared Testimony, Gilmartin stated that prior to the APPROVe trial (a study looking at the protective effects of Vioxx on the risk for colon cancer), the research done by...  

Studies showed substantial cardiovascular dangers linked to the anti-inflammatory medication almost four years before it was taken off the market, new research has concluded. The significant cardiovascular risks linked to Vioxx could have been identified nearly four years before the anti-inflammatory medication was taken off the market, a new study has...  

Clinical trial data indicated an association between the anti-inflammatory medication rofecoxib and cardiovascular risk as early as December 2000, before the product was taken off the market in September 2004, according to a report in the November 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.  

Data now required by US law could have been put to good use in the Vioxx debacle, helping researchers confirm the cardiovascular risk with the drug much earlier than it was eventually pinpointed, say the authors of a new analysis. Heartwire  

The FDA still hasn't restructured its staff to better monitor drug safety, more than three years after experts recommended key changes in the wake of the Vioxx scandal.  

NEW YORK (MarketWatch) -- Merck & Co. said Monday that a district court judge in Travis County, Texas, has granted the company's motion for summary judgment, dismissing all claims in a Vioxx-related lawsuit filed on behalf of the state. That case, filed in 2005 by the Texas attorney general's office, sought damages and penalties from Merck for alleged violations of the Texas Medicaid Fraud Prevention Act. Merck voluntarily withdrew Vioxx from...  

The Supreme Court of Canada today denied leave to appeal in the related cases of Merck Frosst Canada Ltd. v. Benny Mignacca, a decision of the Ontario Court of Appeal, and in Merck Frosst Canada Ltd. v. Gerald Wuttunee, a decision of the Saskatchewan Court of Appeal. The Supreme Court of Canada has therefore left undisturbed the first case in Canada in which class certification has been overturned in pharmaceutical personal injury class...  

Oct. 22 (Bloomberg) -- Merck & Co. lost a bid in the Canadian Supreme Court to put a Vioxx lawsuit on hold in Ontario, while it won a ruling that prevents another case from moving forward as a class action in Saskatchewan.  

Oct. 22 (Bloomberg) -- Merck & Co. lost a bid for a hearing before Canada’s highest court to determine whether competing class-action lawsuits can proceed over claims that the painkiller Vioxx caused heart attacks and strokes.  

A district court judge in Travis County, Texas, dismissed all claims in a Medicaid lawsuit over the discontinued painkiller Vioxx.  

You’d think that after the Vioxx fiasco, Merck might be a little more careful about pushing drugs that don’t offer much benefit. Well, if you did think that, you’d be wrong. A new study in the New England Journal of Medicine this week shows that two very, very profitable cholesterol drugs are pretty much useless. Merck has been at least partly aware of this for 3 years, but they still don't want to admit it – not surprising given that sales...  

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck said today that Travis County, Texas District Court Judge Scott H. Jenkins granted Merck's motion for summary judgment, dismissing all claims in a VIOXX-related lawsuit filed on behalf of the State of Texas. In that case, which was filed in 2005 by the Texas Attorney General's Office, the state sought damages and penalties from Merck for alleged violations of the Texas Medicaid Fraud Prevention...  

Problems with the popular arthritis drug Vioxx, including increased risk for heart attack, stroke and death, were known for years before the drug’s voluntary withdrawal from the market in 2004, a new report says.  

Drug maker said Monday a district court judge in Texas dismissed all claims in a state Medicaid lawsuit over the painkiller Vioxx.  

A study of data revealed in lawsuits suggests Merck should have known Vioxx was deadly years before they pulled the drug from the market. Merck says the study is flawed.  

Congressional investigators say the Food and Drug Administration has not followed through on changes suggested three years ago to better monitor drug safety.  

Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Merck+%28MRK%29+Dismissed+from+All+Travis+County+VIOXX+Claims+/5132354.html for the full story.  

NEW YORK -- Merck & Co. said Monday that a district court judge in Travis County, Texas, has granted the company's motion for summary judgment, dismissing all claims in a Vioxx-related lawsuit filed ...  

Lawyers for Merck told the Supreme Court Monday investors waited too late and didn't do all of the necessary investigations to ...  

WASHINGTON, Nov. 2 (UPI) -- The Obama administration filed a brief with the U.S. Supreme Court siding with investors hoping to sue Merck and Co. over its now-withdrawn painkiller Vioxx.  

AFP - The risks of taking anti-inflammatory drug Vioxx could have been detected nearly four years before the drug was pulled from the market, according to analysis of nearly 30 clinical trials.  

ReutersConsumers didn't have the information they needed on this lemon: VioxxLos Angeles TimesThey point out that the FDA, as the repository of post-marketing surveillance studies, is a weak opponent to the media-savvy and heavily funded ...Bringing the fda's Information to MarketArchives of Internal MedicineVioxx risks could have been identified years earlierLos Angeles Timesall 147 news articles »  

When Richard Clark was named CEO and president of Merck in 2005, the drug behemoth was reeling in the wake of the Vioxx scandal, which in 2004 forced the company to withdraw the blockbuster painkiller for safety reasons.  

Lawyers for Merck & Co have told the US Supreme Court that investors shouldn't have waited so long to sue the drug maker over warnings about the risks of its painkiller Vioxx.  

Birmingham StarOn Merck's Interesting Supreme Court ArgumentWall Street Journal (blog)Williams & Connolly's Kannon Shanmugam is, by many accounts, a rising star of the Supreme Court bar. As an assistant to the Solicitor General ...'Nothing is more important than patient safety'Irish TimesSome Justices Voice Skepticism of Merck in Vioxx CaseWall Street Journalall 201 news articles »  

A new American report suggests that clinical trial data had pointed out the association between the anti-inflammatory drug rofecoxib and cardiovascular risk ne  

The red flags about the pain reliever Vioxx were present at least three years before the drug was taken off the market, U.S. researchers say.